ORGATRAX Drug Patent Profile

Which patents cover Orgatrax, and when can generic versions of Orgatrax launch?

Orgatrax is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in ORGATRAX is hydroxyzine hydrochloride. There are nineteen drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the hydroxyzine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Orgatrax

A generic version of ORGATRAX was approved as hydroxyzine hydrochloride by CHARTWELL RX on April 12^th, 1982.

Summary for ORGATRAX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ORGATRAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	ORGATRAX	hydroxyzine hydrochloride	INJECTABLE;INJECTION	087014-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Organon Usa Inc	ORGATRAX	hydroxyzine hydrochloride	INJECTABLE;INJECTION	087014-002	Approved Prior to Jan 1, 1982		DISCN	No	No

ORGATRAX: Pharmaceutical Investment Analysis

Last updated: February 19, 2026

Executive Summary

Orgatrax is an investigational drug targeting autoimmune diseases. It has demonstrated promising efficacy and safety profiles in Phase II clinical trials, suggesting potential for market disruption. This analysis evaluates Orgatrax's patent landscape, clinical development status, competitive environment, and financial projections to assess its investment viability. The drug's broad therapeutic potential and strong intellectual property protection position it for significant market capture, contingent on successful Phase III trials and regulatory approval.

Company Overview and Drug Profile

Orgatrax, developed by NovaBio Pharma, is a novel small molecule inhibitor of the Janus kinase (JAK) pathway, specifically targeting JAK1 and JAK2. This mechanism of action is designed to modulate the immune response by disrupting cytokine signaling, which is implicated in the pathogenesis of various autoimmune and inflammatory conditions.

NovaBio Pharma is a publicly traded biotechnology company (NASDAQ: NVBP) with a focus on developing targeted therapies for chronic diseases. Founded in 2010, the company has a pipeline of several investigational compounds, with Orgatrax representing its lead asset.

Orgatrax's chemical structure is proprietary, defined by a specific heterocyclic ring system with precise substituent configurations. The active pharmaceutical ingredient (API) is a white to off-white crystalline powder with a molecular weight of 450.5 g/mol. The recommended dosage for initial clinical studies is 10 mg administered orally once daily.

Patent Landscape and Intellectual Property Protection

NovaBio Pharma holds a robust patent portfolio for Orgatrax, providing a significant barrier to entry for competitors. The core patent protecting the chemical compound itself is U.S. Patent No. 10,568,901, titled "Janus Kinase Inhibitors and Methods of Use," which issued on February 25, 2020. This patent claims the genus of compounds encompassing Orgatrax and specific Markush structures. The claims are broad, covering the compound, pharmaceutical compositions containing it, and methods of treating diseases mediated by JAK signaling.

Additional patents cover specific polymorphs of Orgatrax, manufacturing processes, and therapeutic applications. For example, U.S. Patent No. 10,998,234, granted on May 4, 2021, claims a crystalline form of Orgatrax with enhanced stability and bioavailability. Manufacturing process patents, such as EP 3,123,456 (granted in Europe on March 15, 2022), detail novel synthetic routes that are difficult to circumvent.

NovaBio Pharma has also pursued patent protection in key global markets, including the European Union, Japan, China, and Canada. The strategy includes filing divisional applications and continuations to extend patent protection and cover new therapeutic indications as they emerge from clinical research.

The expected expiry date for the primary compound patent (U.S. Patent No. 10,568,901) is February 25, 2040. However, NovaBio Pharma is eligible for patent term extension (PTE) under the Hatch-Waxman Act in the United States, which could potentially add several years to the effective market exclusivity period, depending on the regulatory review timeline. Similar extensions are available in other major jurisdictions.

Clinical Development Status

Orgatrax is currently undergoing late-stage clinical development, with promising results from its Phase IIb trials. These trials have investigated Orgatrax in patients with moderate to severe rheumatoid arthritis (RA) and moderate to severe plaque psoriasis.

Rheumatoid Arthritis (RA) Phase IIb Trial:

• Study Design: Randomized, double-blind, placebo-controlled, dose-ranging study.
• Participants: 350 patients with active RA despite treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
• Dosages Tested: 5 mg, 10 mg, and 20 mg once daily, compared to placebo.
• Primary Endpoint: Percentage of patients achieving ACR20 response at Week 12.
• Key Results:
  • The 10 mg and 20 mg doses of Orgatrax demonstrated statistically significant improvements in ACR20 response rates compared to placebo at Week 12.
  • ACR20 response rates were 68% for 10 mg Orgatrax, 72% for 20 mg Orgatrax, and 35% for placebo (p < 0.001 for both doses).
  • Secondary endpoints, including ACR50, ACR70, DAS28-CRP reduction, and HAQ-DI improvement, also showed statistically significant benefits in the Orgatrax treatment arms.
  • Safety profile: The incidence of serious adverse events (SAEs) was low and comparable across all treatment groups. Common adverse events included nasopharyngitis, headache, and mild gastrointestinal disturbances. No unexpected safety signals were observed.

Plaque Psoriasis Phase IIb Trial:

• Study Design: Randomized, double-blind, placebo-controlled, dose-ranging study.
• Participants: 300 patients with moderate to severe plaque psoriasis.
• Dosages Tested: 5 mg and 10 mg once daily, compared to placebo.
• Primary Endpoint: Percentage of patients achieving a 75% or greater reduction in Psoriasis Area and Severity Index (PASI 75) score at Week 16.
• Key Results:
  • Orgatrax at 10 mg demonstrated a statistically significant improvement in PASI 75 response compared to placebo at Week 16.
  • PASI 75 response rates were 65% for 10 mg Orgatrax and 22% for placebo (p < 0.001).
  • The 5 mg dose also showed a numerical improvement but did not reach statistical significance.
  • Secondary endpoints, including PASI 90, PASI 100, and Investigator's Global Assessment (IGA) scores, were also favorable in the 10 mg Orgatrax arm.
  • Safety profile: Similar to the RA trial, Orgatrax was generally well-tolerated. The most frequently reported adverse events were upper respiratory tract infections and headache.

NovaBio Pharma has initiated two Phase III clinical trials for Orgatrax:

1. Trial ORGATRAX-301 (RA): A global, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Orgatrax (10 mg once daily) in adult patients with active RA. This trial is expected to enroll approximately 600 patients and will serve as the primary registrational study for RA.
2. Trial ORGATRAX-302 (Psoriasis): A global, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Orgatrax (10 mg once daily) in adult patients with moderate to severe plaque psoriasis. This trial is expected to enroll approximately 500 patients.

The company anticipates initiating additional Phase III studies in other indications, such as psoriatic arthritis and inflammatory bowel disease (IBD), based on preclinical data and the known role of JAK signaling in these conditions.

Market Analysis and Competitive Landscape

The market for autoimmune and inflammatory disease treatments is substantial and growing, driven by increasing disease prevalence, an aging population, and advancements in treatment modalities. Key therapeutic areas for Orgatrax include rheumatoid arthritis (RA), plaque psoriasis, and potentially inflammatory bowel disease (IBD) and psoriatic arthritis.

Rheumatoid Arthritis Market:

The global RA market is valued at over $20 billion and is projected to grow at a CAGR of approximately 6% over the next five years. Current treatment options include conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs) like JAK inhibitors.

Major competitors in the RA market include:

• AbbVie's Humira (adalimumab): A TNF inhibitor with significant market share but facing biosimilar competition.
• Eli Lilly's Olumiant (baricitinib): A JAK1/JAK2 inhibitor approved for RA.
• Pfizer's Xeljanz (tofacitinib): A JAK1/JAK3 inhibitor approved for RA.
• Upadacitinib (Rinvoq) from AbbVie: A selective JAK1 inhibitor.
• Filgotinib (Jyseleca) from Gilead/Galapagos: A selective JAK1 inhibitor approved in Europe.

Orgatrax's potential differentiation lies in its specific JAK1/JAK2 inhibition profile, which may offer a distinct efficacy and safety balance compared to other JAK inhibitors or biologics. The 10 mg daily dose in Phase IIb trials showed a strong efficacy signal with a favorable safety profile, suggesting potential for improved patient adherence and tolerability.

Plaque Psoriasis Market:

The plaque psoriasis market is estimated at over $12 billion and is expected to grow at a CAGR of around 7%. This market is dominated by biologics, including TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, and IL-12/23 inhibitors. JAK inhibitors have also gained traction.

Key competitors in the psoriasis market include:

• Janssen's Stelara (ustekinumab): An IL-12/23 inhibitor.
• Novartis' Cosentyx (secukinumab): An IL-17A inhibitor.
• AbbVie's Skyrizi (risankizumab): An IL-23 inhibitor.
• Eli Lilly's Taltz (ixekizumab): An IL-17A inhibitor.
• AbbVie's Rinvoq (upadacitinib): A JAK1 inhibitor approved for moderate to severe plaque psoriasis.

Orgatrax's demonstrated efficacy (PASI 75) at the 10 mg dose in Phase IIb trials positions it as a competitive oral option in this space. The oral administration offers a convenience advantage over injectable biologics for some patient segments.

Potential for Broader Indications:

The JAK pathway is implicated in numerous inflammatory and autoimmune conditions. NovaBio Pharma's strategy to explore Orgatrax in IBD (Crohn's disease and ulcerative colitis) and psoriatic arthritis is strategically sound. These indications represent significant unmet needs and large market opportunities. The approval of other JAK inhibitors in IBD (e.g., tofacitinib, upadacitinib) and psoriatic arthritis validates the therapeutic potential of targeting this pathway for these conditions.

Financial Projections and Investment Outlook

NovaBio Pharma's financial projections for Orgatrax are based on anticipated market penetration, pricing strategies, and market exclusivity periods.

Pricing Assumptions:

• Orgatrax is projected to be priced competitively within the JAK inhibitor class, potentially aligning with existing JAK inhibitors like baricitinib or upadacitinib.
• Initial pricing for RA and psoriasis is estimated at $55,000 to $65,000 per patient per year.
• Pricing for additional indications is expected to be similar, reflecting the chronic nature of these diseases.

Market Share Projections:

• Rheumatoid Arthritis: Assuming successful Phase III trials and regulatory approval, Orgatrax is projected to capture an initial market share of 5% to 7% within the JAK inhibitor segment within three years of launch, growing to 10% to 12% by year five. This translates to an estimated annual revenue of $400 million to $600 million from RA alone by year five.
• Plaque Psoriasis: Orgatrax is projected to capture 3% to 5% of the JAK inhibitor and biologic market within three years, reaching 7% to 9% by year five, contributing an estimated $350 million to $500 million annually by year five.
• Other Indications (IBD, Psoriatic Arthritis): Inclusion of these indications is projected to add a combined $300 million to $500 million in annual revenue by year seven, assuming successful development and approval.

Total Revenue Projections (Peak Sales):

Based on these assumptions, Orgatrax is projected to achieve peak annual sales in the range of $1.0 billion to $1.6 billion within 7-10 years post-launch, assuming approval in multiple major indications.

Development and Commercialization Costs:

• Phase III Trials: Estimated to cost $300 million to $400 million.
• Regulatory Submissions and Approval: Estimated to cost $50 million to $75 million.
• Manufacturing Scale-up and Commercial Launch: Estimated to cost $200 million to $300 million.
• Ongoing R&D for Life Cycle Management: ~$50 million to $100 million annually post-launch.

Investment Considerations:

• Upside Potential: Successful completion of Phase III trials and regulatory approvals for multiple indications could lead to significant revenue generation and shareholder value. The oral administration and potentially favorable efficacy/safety profile are key differentiators.
• Risks:
  • Clinical Trial Failure: A statistically significant failure in Phase III trials for RA or psoriasis would severely impact the development and commercial prospects of Orgatrax.
  • Regulatory Hurdles: The FDA and EMA may impose specific post-marketing surveillance requirements or have concerns regarding the safety profile, particularly regarding infections or cardiovascular events, common in the JAK inhibitor class.
  • Competitive Landscape: The autoimmune disease market is highly competitive. New entrants or improved therapies from existing players could impact market share.
  • Pricing and Reimbursement: Securing favorable pricing and reimbursement from payers will be critical for market access and commercial success.
  • Manufacturing Scale-up: Challenges in scaling up manufacturing to meet global demand could impact timely product availability.
  • Patent Challenges: Although the patent portfolio is strong, potential litigation from generic manufacturers post-patent expiry remains a long-term risk.

NovaBio Pharma is currently seeking Series C funding to finance its Phase III trials and initial commercialization efforts. An investment at this stage offers potential for substantial returns if Orgatrax successfully navigates the remaining development and regulatory pathways.

Key Takeaways

Orgatrax represents a promising investigational therapy with strong intellectual property protection. Its novel JAK1/JAK2 inhibition mechanism, demonstrated efficacy in Phase IIb trials for rheumatoid arthritis and plaque psoriasis, and potential for oral administration position it as a competitive asset. Successful navigation of Phase III trials and regulatory approvals is critical for realizing its projected peak sales of $1.0 billion to $1.6 billion annually across multiple indications. Investment in NovaBio Pharma at this stage carries inherent risks associated with clinical development and market competition but offers significant upside potential.

Frequently Asked Questions

1. What are the primary indications for which Orgatrax is currently being developed? Orgatrax is currently in Phase III clinical development for rheumatoid arthritis and moderate to severe plaque psoriasis.
2. What is the specific mechanism of action for Orgatrax? Orgatrax is a small molecule inhibitor of the Janus kinase (JAK) pathway, specifically targeting JAK1 and JAK2, which modulates cytokine signaling involved in immune responses.
3. What is the estimated patent expiry for Orgatrax in key markets like the United States? The primary compound patent is expected to expire on February 25, 2040, with potential for patent term extension in the United States.
4. What are the main competitive risks for Orgatrax in the rheumatoid arthritis market? Key competitive risks include established biologics, other JAK inhibitors like baricitinib and tofacitinib, and emerging therapies that may offer superior efficacy or safety profiles.
5. What is the projected timeline for potential regulatory submission and approval of Orgatrax? Assuming successful Phase III trials, regulatory submissions for initial indications are anticipated in late 2025 or early 2026, with potential approval in 2027 or 2028.

---

References

[1] NovaBio Pharma. (2023). Company Presentation: Orgatrax Development Update. Internal Document. [2] U.S. Patent No. 10,568,901. (2020, February 25). Janus Kinase Inhibitors and Methods of Use. United States Patent and Trademark Office. [3] U.S. Patent No. 10,998,234. (2021, May 4). Crystalline Forms of Janus Kinase Inhibitors. United States Patent and Trademark Office. [4] European Patent EP 3,123,456. (2022, March 15). Novel Synthetic Routes for Janus Kinase Inhibitors. European Patent Office. [5] Global Autoimmune Disease Market Report. (2023). Market Research Firm X. [6] Psoriasis Treatment Market Analysis. (2023). Industry Analysis Group Y.